Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

1.6K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.6K
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

3.0K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.0K
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

3.9K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
3.9K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

1.1K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.1K
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

920
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
920
Hypersensitivities01:30

Hypersensitivities

6.2K
Hypersensitivity, also known as a hypersensitivity reaction or allergic reaction, is a condition where the body's immune system reacts abnormally to a foreign substance. Such substances, that cause hypersensitivity are referred to as an allergen, could be something typically harmless to most people, like pollen or certain foods.
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
6.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Distinctive Reactivity to the C-terminal Epitope of BP180 Characterizes Immune Checkpoint Inhibitor-associated Bullous Pemphigoid, and an ELISA Based on the BP180 Ectodomain Enables Prompt Diagnosis in a Subset of Patients.

Acta dermato-venereologica·2026
Same author

Treatment-associated phenotype switching between psoriasis and atopic dermatitis.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

The Multifaceted Role of Keratinocytes in Hidradenitis Suppurativa Pathogenesis.

Experimental dermatology·2026
Same author

Exploratory Volatilome Profiling of Inflammation in Skin Fibroblasts: A Proof-of-Concept Study.

International journal of molecular sciences·2026
Same author

International development of Investigator Global Assessment scores for pemphigus.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

European S2k guidelines on management of autoimmune blistering diseases in children and adolescents.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same journal

Circulating Tumor DNA as a Biomarker for Melanoma Prognosis and Therapy.

American journal of clinical dermatology·2026
Same journal

Defining the Potential for Disease Modification in Atopic Dermatitis.

American journal of clinical dermatology·2026
Same journal

Atopic Dermatitis: New Targets and Emerging Systemic Therapies.

American journal of clinical dermatology·2026
Same journal

Rethinking Head and Neck Atopic Dermatitis: Pathogenic Axes and Emerging Therapeutic Directions.

American journal of clinical dermatology·2026
Same journal

Correction: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program.

American journal of clinical dermatology·2026
Same journal

A Systematic Review of the Clinical Impact of GLP-1 Receptor Agonists in Hidradenitis Suppurativa.

American journal of clinical dermatology·2026
See all related articles

Related Experiment Video

Updated: Dec 21, 2025

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis
03:23

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis

Published on: May 10, 2024

1.2K

Eosinophilic Dermatoses: Recognition and Management.

Angelo Valerio Marzano1,2, Giovanni Genovese3,4

  • 1Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. angelo.marzano@unimi.it.

American Journal of Clinical Dermatology
|May 13, 2020
PubMed
Summary
This summary is machine-generated.

Eosinophilic dermatoses are skin conditions marked by eosinophil buildup. This study classifies these diverse diseases into six groups based on where they affect the skin, aiding diagnosis and management.

More Related Videos

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus
05:39

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus

Published on: May 16, 2025

454
Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
10:27

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

24.9K

Related Experiment Videos

Last Updated: Dec 21, 2025

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis
03:23

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis

Published on: May 10, 2024

1.2K
Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus
05:39

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus

Published on: May 16, 2025

454
Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
10:27

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

24.9K

Area of Science:

  • Dermatology
  • Pathology
  • Immunology

Background:

  • Eosinophilic dermatoses present a wide array of clinical manifestations and etiologies.
  • Current classification systems for these conditions are not universally standardized.
  • These diseases are characterized by eosinophilic infiltration of the skin and/or mucous membranes, potentially with blood eosinophilia.

Purpose of the Study:

  • To propose a novel classification system for eosinophilic dermatoses based on the predominant anatomic level of involvement.
  • To review the clinicopathologic features and management strategies for diseases within each proposed category.
  • To provide a structured framework for understanding and managing this diverse group of skin conditions.

Main Methods:

  • Identification of six distinct groups of eosinophilic dermatoses based on the primary site of tissue involvement (epidermal, dermal-epidermal junction, dermal, hypodermal/fascial, pilosebaceous unit, vascular/perivascular).
  • Review of clinicopathologic features and therapeutic approaches for representative diseases within each group.
  • Synthesis of information to create a comprehensive overview of eosinophilic dermatoses.

Main Results:

  • Six groups of eosinophilic dermatoses were defined: epidermal, dermal-epidermal junction, dermal, hypodermal/fascial, pilosebaceous unit, and vascular/perivascular.
  • Specific diseases were assigned to each group, including examples like atopic dermatitis, bullous pemphigoid, Wells syndrome, DRESS syndrome, eosinophilic fasciitis, eosinophilic pustular folliculitis, and granuloma faciale.
  • The classification highlights the diverse presentations and locations of eosinophilic infiltration in the skin.

Conclusions:

  • The proposed classification based on anatomic level provides a structured approach to understanding eosinophilic dermatoses.
  • This framework facilitates a comprehensive review of clinicopathologic features and management of these conditions.
  • Improved classification may aid in diagnosis, research, and therapeutic strategies for eosinophilic skin diseases.